Lonza Walkersville, Inc v. Miltenyi Biotec North America, Inc.

CourtDistrict Court, D. Maryland
DecidedDecember 3, 2024
Docket8:22-cv-00220
StatusUnknown

This text of Lonza Walkersville, Inc v. Miltenyi Biotec North America, Inc. (Lonza Walkersville, Inc v. Miltenyi Biotec North America, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Maryland primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Lonza Walkersville, Inc v. Miltenyi Biotec North America, Inc., (D. Md. 2024).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND

*

LONZA WALKERSVILLE, INC., et al., *

Plaintiffs, *

v. * Civil Action No. 22-cv-0220-PX

MILTENYI BIOTEC, INC., *

Defendant. * ****** MEMORANDUM OPINION

Pending in this patent infringement action is Defendant’s motion for claim construction pertinent to multiple claim terms in U.S. Patent Nos. 9,534,195 (the “’195 Patent”); 9,701,932 (the “’932 Patent”); 10,723,986 (the “’986 Patent”); and 10,844,338 (the “’338 Patent”) (collectively, the “Smith Patents”). After holding a technology tutorial and Markman hearing, ECF Nos. 63 & 73, and having considered the relevant claim language, specifications and embodiments, this Court now construes the disputed terms. I. Background In 2014, Lonza Walkersville, Inc. (“Lonza”), a Maryland-based manufacturer of pharmaceutical products, began its joint venture with Octane Biotech, Inc. (“Octane”) to further develop and commercialize the Cocoon® Platform, an “all-in-one” system that “facilitates the use of cell therapy” through “digital monitoring and control of temperature, gases, pH, and dissolved oxygen.” ECF No. 1 ¶¶ 9, 15, 17. After years of work and collaboration with Lonza on cell therapy treatments, Octane was granted a series of patents related to “automated bioreactor technology,” including the Smith Patents. Id. ¶¶ 20, 21, 23, 25, & 27. The Smith Patents are part of the same patent family and derive from U.S. Patent No. 8,492,140 (the “140 Patent” or “Parent Patent”). ECF No. 81 at 5.1 See also ECF No. 83 at 9. The Smith Patents each have identical specifications and embodiments, but different claims. ECF No. 1 ¶¶ 22–28. See also ECF Nos. 42-5–8. Generally, the Smith Patents cover cell culture and tissue engineering techniques for

various types of cellular implants. Specifically, the patents describe a system “capable of automatically evaluating and manipulating the changing environment surrounding the developing implant such that cells progressively proliferate and differentiate into a desired implant,” minimizing “human error” or need “of continual [cell] performance evaluation.” ECF No. 42-5 at 26. The patents contribute a “fully automated” system that “modif[ies] the environment to support tissue development” using sensors and a microprocessor. Id. at 26–27. The Smith Patents, in short, cover a system that overall minimizes human intervention by automatically adjusting necessary parameters such as pH, temperature, gasses and nutrition during a series of tissue development stages. Id. at 27. In 2013, Defendant Miltenyi Biotech, Inc. (“Miltenyi”), a direct competitor of Lonza,

launched its ClinicMACS Prodigy® Instrument. ECF No. 42 at 7; ECF No. 1 ¶ 29. Lonza maintains that Miltenyi’s device also employs cell engineering techniques that include a “fully automated, sensor-controlled process” “to maintain optimal conditions” for cell processing. ECF No. 1 ¶¶ 30–32. Thus, Lonza says the Prodigy infringes on the Smith Patents and accordingly, filed suit against Miltenyi for patent infringement. ECF No. 1 ¶¶ 68–99. Plaintiffs twice amended the complaint to correct Defendant’s corporate name, ECF No. 22-1 at 1, and to add infringement counts related to two other patents (U.S. Patent Nos. 11,371,018 and 11,447,745),

1 Lonza chose not to assert infringement of the ’140 Patent. See ECF No. 83 at 34; ECF No. 37 ¶ 2. ECF No. 37-1 at 1–2. The Parties next moved for this Court to construe certain claims included in the Smith Patents only.2 ECF Nos. 41, 42, 56 & 57. A. The Parties’ Proposed Constructions The Parties dispute several claim terms across the four Smith Patents. ECF No. 40-1.

First, the Parties dispute whether the term “automatically” is sufficiently clear as written and when modifying terms such as “monitoring,” “altering,” “adjusting,” and “readjust(ing).3 ECF No. 40-1 (Patents ’195, ’932, ’986, ’338). Second, the Parties dispute whether the term “parameters” is to mean more than one parameter. Id. at 6. Third, the Parties dispute the meaning of “a proliferation substrate or scaffold supported within the bioreactor.” Id. Fourth, Defendant Miltenyi argues the phrase “such that optimal conditions are maintained” is indefinite. Id. Plaintiffs contend that the disputed terms are clear as written and do not require any claim construction. ECF No. 41 at 17–18. That said, Plaintiffs propose alternative constructions than those Miltenyi supports in the event the Court determines the claim terms are ambiguous as

written. The Parties’ proposed constructions appear in bold and underlined text below: Claim Terms and Phrases Lonza’s Proposed Miltenyi’s Proposed (Patent, Claim) Construction Construction “ . . . one or more sensors for Plain and ordinary meaning Plain and ordinary meaning: monitoring and automatically . . . one or more sensors for If construction needed: adjusting parameters related to monitoring and automatically . . . one or more sensors for said cellular functions and/or adjusting, without in process, monitoring and automatically generation of tissue constructs external (human) input, transmitting to a controller parameters related to said or microprocessor for . . . cellular functions adjusting parameters related to

said cellular functions and/or

2 On May 19, 2023, Parties stipulated to dismiss with prejudice the two additional patent infringement claims related to the Shi Patents. ECF No. 50. 3 The Parties construe “active” and “actively” in the same manner as they construe “automatically,” and the court treats them together. ECF No. 41 at 17. generation of tissue constructs . . . The bioreactor is adapted to . . . and to automatically re- . . . The bioreactor is adapted adjust the parameters in the to . . . and to automatically re- bioreactor responsive to the the bioreactor is adapted to adjust, without in process, status of cell proliferation automatically monitor external (human) input and and/or tissue formation to parameters relayed by the one via a microprocessor, the generate a desired cell or more sensors such that parameters related to said population and/or tissue optimal conditions are cellular functions and/or construct in the bioreactor.” maintained in the bioreactor generation of tissue constructs and to automatically re-adjust, in the bioreactor in a manner (’195 Patent, claim 1 and all without necessarily requiring that is responsive to changes asserted dependent claims) human input, the parameters in these parameters caused in the bioreactor responsive to by the status of cell the status of cell proliferation proliferation and/or tissue and/or tissue formation to formation to generate a desired generate a desired cell cell population and/or tissue population and/or tissue construct in the bioreactor. For construct in the bioreactor. avoidance of doubt, automatically adjusting and re-adjusting parameters is distinct from maintaining pre-set and pre-determined parameters. “ . . . said one or more sensors Plain and ordinary meaning Plain and ordinary operatively generate signals meaning: If construction needed: to a central and/or onboard . . . said one or more sensors . . .

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Lonza Walkersville, Inc v. Miltenyi Biotec North America, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/lonza-walkersville-inc-v-miltenyi-biotec-north-america-inc-mdd-2024.